Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05705024 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells
A Phase 2 study of Corneal Ulcer, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 4
- Study locations
NCT05705024: Recruiting Phase 2 study of Corneal Ulcer, sponsored by University of Illinois at Chicago.
NCT05705024 is a Phase 2 study of Corneal Ulcer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05705024, a Phase 2 study of Corneal Ulcer, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 4
- Study locations
Study Summary
The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.
Primary Outcome
The proportion of patients with improved epithelial barrier and/or integrity from baseline to DAY 28 as determined by the investigator on slit lamp examination: * Improved epithelial barrier, defined as a 50 % improvement in corneal fluorescein staining score * Improved epithelial integrity, defined as a healed epithelial defect
Conditions Studied
Interventions
- BIOLOGICAL Mesenchymal Stromal Cells
- OTHER Control Solution
Study Locations (4)
Illinois
- Department of Ophthalmology and Visual Sciences - Chicago
Maryland
- University of Maryland at Baltimore - Baltimore
Massachusetts
- Mass Eye and Ear Infirmary - Boston
Pennsylvania
- University of Pennsylvania, Scheie Eye Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-09-29 |
| Est. Completion | 2026-09-28 |
| Phase | Phase 2 |
What NCT05705024 shows while recruiting
NCT05705024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Corneal Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Mesenchymal Stromal Cells is the first listed.
NCT05705024 reports a single indexed study location in Illinois, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05705024 about?
NCT05705024 is a clinical study titled "Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells". The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0...
What is the current status of trial NCT05705024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2023-09-29. Estimated completion is 2026-09-28.
What conditions does trial NCT05705024 study?
This clinical trial studies the following conditions: Corneal Ulcer.
What interventions are being tested in trial NCT05705024?
The interventions under investigation include: Mesenchymal Stromal Cells (BIOLOGICAL), Control Solution (OTHER).
Who is sponsoring clinical trial NCT05705024?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05705024 being conducted?
This trial has 4 study locations across Illinois, Maryland, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05705024's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI